D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock. D. Boral Capital’s target price suggests a potential upside of 138.65% from the stock’s current price.

Other research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research note on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Finally, WBB Securities restated a “strong-buy” rating and set a $45.00 price target on shares of Omeros in a research note on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.67.

Omeros Stock Up 72.4%

OMER stock opened at $15.09 on Wednesday. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -7.47 and a beta of 2.48. The business has a fifty day moving average of $8.91 and a two-hundred day moving average of $5.73.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39. As a group, sell-side analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Omeros

A number of hedge funds have recently bought and sold shares of OMER. B. Riley Wealth Advisors Inc. acquired a new position in shares of Omeros during the second quarter worth about $32,000. Harbour Investments Inc. lifted its stake in Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 4,251 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 11,971 shares in the last quarter. Sei Investments Co. purchased a new stake in shares of Omeros in the 2nd quarter valued at approximately $40,000. Finally, Russell Investments Group Ltd. increased its holdings in Omeros by 113.1% in the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 5,677 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Key Headlines Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: FDA approval — The FDA approved YARTEMLEA as the first and only therapy indicated for transplant‑associated thrombotic microangiopathy (TA‑TMA), validating Omeros’ first‑in‑class lectin pathway program and creating a clear path to initial commercial revenues. FDA Approves Omeros’ YARTEMLEA — Business Wire
• Positive Sentiment: Market reaction — Shares surged on the approval, with heavy intraday volume and multiple trading halts/LULD pauses as buyers chased the stock; this suggests strong short‑term retail and institutional demand. Omeros Shares Surge on FDA Approval — MarketWatch
• Positive Sentiment: Analyst re‑rating potential — Several firms reiterated or maintained buy ratings and raised targets following the approval (examples cited: D. Boral Capital $36 PT; H.C. Wainwright $20 PT), supporting upside expectations as revenue modeling shifts from probability‑adjusted to actual launch assumptions. Ratings & Re‑rating Potential — TipRanks
• Positive Sentiment: Retail and options activity — Unusually large retail interest and a big spike in call option volume indicate speculative positioning ahead of and after the approval, amplifying intraday moves and liquidity. Why Omeros Stock Skyrocketed Today — The Motley Fool
• Neutral Sentiment: Valuation re‑assessment — Commentary and analysis pieces are revisiting Omeros’ valuation after a multi‑year share repricing; longer‑term upside depends on commercial execution, pricing, and uptake in the TA‑TMA indication. Revisiting Valuation After Share Repricing — Yahoo Finance
• Neutral Sentiment: Short interest reporting appears inconsistent — December short‑interest entries show anomalous/zero values and a 0.0 days‑to‑cover figure, implying the published data may be unreliable for gauging short exposure right now.
• Negative Sentiment: Execution and volatility risk — Trading halts, a big intraday repricing, high beta and speculative options flow raise the risk of sharp reversals if early commercial data, pricing, or hospital adoption falls short of investor expectations; Omeros remains a cash‑burning biotech with execution risk into commercialization.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.